Magenta Therapeutics Financing
Magenta Therapeutics, Inc., Corporation just filed form D announcing $48.66 million equity financing. This is a new filing. Magenta Therapeutics was able to sell $17.72 million so far. That is 36.41% of the round of financing. The total fundraising amount was $48.66 million. The private financing document was filed on 2016-11-18. The reason for the financing was: unspecified. The fundraising still has about $30.95 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Magenta Therapeutics is based in Massachusetts. The filler’s business is Biotechnology. The D form was signed by Jason Gardner President. The company was incorporated in 2015. The filler’s address is: 245 First Street, 4Th Floor, Cambridge, Ma, Massachusetts, 02142. Jason Gardner is the related person in the form and it has address: 245 First Street, 4Th Floor, Cambridge, Ma, Massachusetts, 02142. Link to Magenta Therapeutics Filing: 000169058516000001.
Analysis of Magenta Therapeutics Offering
On average, firms in the Biotechnology sector, sell 73.77% of the total offering size. Magenta Therapeutics sold 36.41% of the offering. The fundraising is still open. The average investment floor size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 475.29% bigger than the average for companies in the Biotechnology sector. The minimum investment for this fundraising was set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Magenta Therapeutics Also
The Form D signed by Jason Gardner might help Magenta Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.